Biblio Discovery — Demo Discovery Service

20 hasil untuk "Maria E. Rodriguez"

Menampilkan 1–20 · 0,81 detik · RSS

  1. Artikel Jurnal

    Cancer-associated fibroblast targeting therapies as a tool to enhance responses to radiotherapy and immunotherapy

    Maria E Rodriguez-Ruiz; Eneko Garate-Soraluze; Iñigo Martinez-Zubiaurre

    Journal for ImmunoTherapy of Cancer, Vol. 14 No. 5 · 2026 · Inggris · DOAJ Scopus

    Cancer-associated fibroblasts (CAFs) are one of the main components of the tumor microenvironment (TME) of solid tumors. They have several functions, which all contribute to tumor growth and immune evasion. CAF presence is associated with poor clinical response to standard therapy and…

  2. Artikel Jurnal

    Adult-onset asthma and periocular xanthogranulomas associated with systemic IgG4-related disease

    Christopher K.H. Burris; Maria E. Rodriguez; Meisha L. Raven dkk.

    American Journal of Ophthalmology Case Reports, Vol. 1 No. C · 2016 · Inggris · DOAJ Scopus

    Purpose: The aim of this study was to report a case of Adult-Onset Asthma with Periocular Xanthogranulomas (AAPOX) associated with systemic IgG4-related disease (IgG4-RD). Observations: A 57-year-old man presented with bilateral periorbital swelling for 1 year. Histopathology of a left orbital…

  3. Artikel Jurnal Teks lengkap

    Treatment of canine leishmaniasis with marbofloxacin in dogs with renal disease

    Carmen Pineda; Escolastico Aguilera-Tejero; Maria C. Morales dkk.

    PLOS ONE, Vol. 12 No. 10 · 2017 · Inggris · PLOS Scopus

    Treatment of canine leishmaniasis (CanL) represents a challenge. Due to the high prevalence of renal disease associated to CanL, it is important to find an effective drug that does not damage the kidneys. Marbofloxacin has been shown to be effective and well tolerated in non-azotemic dogs with…

    Juga tersedia di: DOAJ

  4. Artikel Jurnal

    Muir-Torre Syndrome: The Importance of a Detailed Family History

    Christopher K.H. Burris; Maria E. Rodriguez; Meisha L. Raven dkk.

    Case Reports in Ophthalmology, Vol. 10 No. 2 · 2019 · Inggris · DOAJ Scopus

    Muir-Torre syndrome, a variant of Lynch syndrome or hereditary nonpolyposis colorectal cancer, is an autosomal dominant disease characterized by skin neoplasms (sebaceous or keratoacanthomas) and visceral malignancies. Due to the rarity of the syndrome there are no firm guidelines on how and when…

  5. Artikel Jurnal

    A Retroviral Replicating Vector Encoding Cytosine Deaminase and 5-FC Induces Immune Memory in Metastatic Colorectal Cancer Models

    Kader Yagiz; Maria E. Rodriguez-Aguirre; Fernando Lopez Espinoza dkk.

    Molecular Therapy: Oncolytics, Vol. 8 · 2018 · Inggris · DOAJ

    Treatment of tumors with Toca 511, a gamma retroviral replicating vector encoding cytosine deaminase, followed by 5-fluorocytosine (5-FC) kills tumors by local production of 5-fluorouracil (5-FU). In brain tumor models, this treatment induces systemic anti-tumor immune responses and long-term…

  6. Artikel Jurnal

    Deubiquitinases A20 and CYLD modulate costimulatory signaling via CD137 (4–1BB)

    Arantza Azpilikueta; Elixabet Bolaños; Valerie Lang dkk.

    OncoImmunology, Vol. 7 No. 1 · 2018 · Inggris · DOAJ Scopus

    TRAF2 dependent K63-polyubiquitinations have been recently shown to connect CD137 (4–1BB) stimulation to NF-κB activation. In a search of deubiquitinase enzymes (DUBs) that could regulate such a signaling route, A20 and CYLD were found to coimmunoprecipitate with CD137 and TRAF2 complexes. Indeed…

  7. Artikel Jurnal

    Cellular cytotoxicity is a form of immunogenic cell death

    Pedro Berraondo; Arantza Azpilikueta; Elixabet Bolaños dkk.

    Journal for ImmunoTherapy of Cancer, Vol. 8 No. 1 · 2020 · Inggris · DOAJ Scopus

    Background The immune response to cancer is often conceptualized with the cancer immunity cycle. An essential step in this interpretation is that antigens released by dying tumors are presented by dendritic cells to naive or memory T cells in the tumor-draining lymph nodes. Whether tumor cell death…

  8. Artikel Jurnal

    Intratumoral neoadjuvant immunotherapy based on the BO-112 viral RNA mimetic

    Maite Alvarez; Carmen Molina; Saray Garasa dkk.

    OncoImmunology, Vol. 12 No. 1 · 2023 · Inggris · DOAJ Scopus

    BO-112 is a poly I:C-based viral mimetic that exerts anti-tumor efficacy when intratumorally delivered in mouse models. Intratumoral BO-112 synergizes in mice with systemic anti-PD-1 mAbs and this combination has attained efficacy in PD1-refractory melanoma patients. We sought to evaluate the…

  9. Artikel Jurnal

    Intratumoral BO-112 in combination with radiotherapy synergizes to achieve CD8 T-cell-mediated local tumor control

    Helena Escuin-Ordinas; Ignacio Melero; Marisol Quintero dkk.

    Journal for ImmunoTherapy of Cancer, Vol. 11 No. 1 · 2023 · Inggris · DOAJ Scopus

    Background Radioimmunotherapy combines irradiation of tumor lesions with immunotherapy to achieve local and abscopal control of cancer. Most immunotherapy agents are given systemically, but strategies for delivering immunotherapy locally are under clinical scrutiny to maximize efficacy and avoid…

  10. Artikel Jurnal

    Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies

    Arantza Azpilikueta; Ignacio Melero; Sonia Guedan dkk.

    Journal for ImmunoTherapy of Cancer, Vol. 10 No. 3 · 2022 · Inggris · DOAJ Scopus

    Background On the basis of efficacy in mouse tumor models, multiple CD137 (4-1BB) agonist agents are being preclinically and clinically developed. The costimulatory molecule CD137 is inducibly expressed as a transmembrane or as a soluble protein (sCD137). Moreover, the CD137 cytoplasmic signaling…

  11. Artikel Jurnal

    A randomized phase II clinical trial of dendritic cell vaccination following complete resection of colon cancer liver metastasis

    Javier Rodriguez; Eduardo Castañón; Jose Luis Perez-Gracia dkk.

    Journal for ImmunoTherapy of Cancer, Vol. 6 No. 1 · 2018 · Inggris · DOAJ Scopus

    Abstract Surgically resectable synchronic and metachronic liver metastases of colon cancer have high risk of relapse in spite of standard-of-care neoadjuvant and adjuvant chemotherapy regimens. Dendritic cell vaccines loaded with autologous tumor lysates were tested for their potential to avoid or…

  12. Artikel Jurnal

    NKG2C/KLRC2 tumor cell expression enhances immunotherapeutic efficacy against glioblastoma

    Derek A Wainwright; Aurelio Hernández-Laín; Maria E Rodriguez-Ruiz dkk.

    Journal for ImmunoTherapy of Cancer, Vol. 12 No. 8 · 2024 · Inggris · DOAJ Scopus

    Background Activating and inhibitory receptors of natural killer (NK) cells such as NKp, NKG2, or CLEC are highly relevant to cold tumors including glioblastoma (GBM). Here, we aimed to characterize the expression of these receptors in GBM to gain insight into their potential role as modulators of…

  13. Artikel Jurnal

    4-1BB agonist targeted to fibroblast activation protein α synergizes with radiotherapy to treat murine breast tumor models

    Ignacio Melero; Alvaro Teijeira; Christian Klein dkk.

    Journal for ImmunoTherapy of Cancer, Vol. 13 No. 2 · 2025 · Inggris · DOAJ Scopus

    Background Ionizing radiation (IR) is a double-edged sword for immunotherapy as it may have both immunosuppressive and immunostimulatory effects. The biological effects of IR on the tumor microenvironment (TME) are a key factor for this balance. Fibroblast activation protein (FAP) is expressed on…

  14. Artikel Jurnal

    An international phase II trial and immune profiling of SBRT and atezolizumab in advanced pretreated colorectal cancer

    Antonin Levy; Daphné Morel; Matthieu Texier dkk.

    Molecular Cancer, Vol. 23 No. 1 · 2024 · Inggris · DOAJ Scopus

    Abstract Background Immuno-radiotherapy may improve outcomes for patients with advanced solid tumors, although optimized combination modalities remain unclear. Here, we report the colorectal (CRC) cohort analysis from the SABR-PDL1 trial that evaluated the PD-L1 inhibitor atezolizumab in…

  15. Artikel Jurnal

    Monocyte-lineage tumor infiltration predicts immunoradiotherapy response in advanced pretreated soft-tissue sarcoma: phase 2 trial results

    Antonin Levy; Daphné Morel; Matthieu Texier dkk.

    Signal Transduction and Targeted Therapy, Vol. 10 No. 1 · 2025 · Inggris · DOAJ Scopus

    Abstract Immunoradiotherapy holds promise for improving outcomes in patients with advanced solid tumors, including in soft-tissue sarcoma (STS). However, the ideal combination of treatment modalities remains to be determined, and reliable biomarkers to predict which patients will benefit are…

  16. Artikel Jurnal

    CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials

    Neil H. Segal; Ignacio Melero; Victor Moreno dkk.

    Nature Communications, Vol. 15 No. 1 · 2024 · Inggris · DOAJ Scopus

    Abstract Cibisatamab is a bispecific antibody-based construct targeting carcinoembryonic antigen (CEA) on tumour cells and CD3 epsilon chain as a T-cell engager. Here we evaluated cibisatamab for advanced CEA-positive solid tumours in two open-label Phase 1 dose-escalation and -expansion studies…

  17. Artikel Jurnal

    Considerations for treatment duration in responders to immune checkpoint inhibitors

    Daniel Olson; Jiajia Zhang; Todd Bartkowiak dkk.

    Journal for ImmunoTherapy of Cancer, Vol. 9 No. 3 · 2021 · Inggris · DOAJ Scopus

    Immune checkpoint inhibitors (ICIs) have improved overall survival for cancer patients, however, optimal duration of ICI therapy has yet to be defined. Given ICIs were first used to treat patients with metastatic melanoma, a condition that at the time was incurable, little attention was initially…

  18. Artikel Jurnal

    Conventional type-1 DC density is associated with checkpoint inhibitor response across multiple types of cancer

    Alvaro Lopez-Janeiro; José González-Gomariz; Fadi Issa dkk.

    The Journal of Clinical Investigation, Vol. 136 No. 9 · 2026 · Inggris · DOAJ Scopus

    Conventional type-1 dendritic cells (cDC1) are the main mediators of crosspresentation of tumor antigens to CD8+ T cells and provide a context of costimulatory molecules and cytokines that lead to cytotoxic T lymphocyte (CTL) responses. We analyzed bulk RNA sequences from 7 key clinical trials…